Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
8 evidence topics · 7 sources
Absorption, dephosphorylation to psilocin, and distribution
“Psilocybin is rapidly dephosphorylated to psilocin, which is absorbed with Tmax values ranging from 1.8 to 4 h following oral administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One study reported psilocin bioavailability at 52.7 ± 20%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The volume of distribution was extensive, ranging from 277 ± 92 L to 1016 L, suggesting significant tissue distribution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elimination half-life varied across studies, ranging from 1.5 to 4 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fixed oral doses of 15, 25, and 30 mg: maximal concentration, time to peak, and half-life
Weight-based escalating doses and equivalence of the 25 mg fixed dose
“No psilocybin was found in plasma or urine, and renal clearance of intact psilocin accounted for less than 2% of the total clearance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pharmacokinetics of psilocin were linear within the twofold range of doses, and the elimination half-life of psilocin was 3 h (standard deviation 1.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An extended elimination phase in some subjects suggests hydrolysis of the psilocin glucuronide metabolite.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Simulation of fixed doses using the pharmacokinetic parameters suggest that an oral dose of 25 mg should approximate the drug exposure of a 0.3 mg/kg oral dose of psilocybin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism: glucuronidation by UGT1A10 and UGT1A9
“UGT1A10 exhibited the highest psilocin glucuronidation activity, whereas the activities of UGTs 1A9, 1A8, 1A7, and 1A6 were significantly lower.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“suggest that whereas psilocin may be subjected to extensive glucuronidation by UGT1A10 in the small intestine, UGT1A9 is likely the main contributor to its glucuronidation once it has been absorbed into the circulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolism: monoamine oxidase A, CYP2D6, and CYP3A4
“MAO-A transformed psilocin into minimal amounts of 4-HIAA and 4-HTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the CYP2D6 genotype did not influence psilocin plasma concentrations in the investigated study population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, MAO-A, CYP2D6, and CYP3A4 are involved in psilocin’s metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CYP2D6 and CYP3A4 seem to be involved to a minor extent in psilocin’s metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote